Back to Search Start Over

The impact of the Fungus-Host-Microbiota interplay upon Candida albicans infections: current knowledge and new perspectives.

Authors :
d'Enfert C
Kaune AK
Alaban LR
Chakraborty S
Cole N
Delavy M
Kosmala D
Marsaux B
Fróis-Martins R
Morelli M
Rosati D
Valentine M
Xie Z
Emritloll Y
Warn PA
Bequet F
Bougnoux ME
Bornes S
Gresnigt MS
Hube B
Jacobsen ID
Legrand M
Leibundgut-Landmann S
Manichanh C
Munro CA
Netea MG
Queiroz K
Roget K
Thomas V
Thoral C
Van den Abbeele P
Walker AW
Brown AJP
Source :
FEMS microbiology reviews [FEMS Microbiol Rev] 2021 May 05; Vol. 45 (3).
Publication Year :
2021

Abstract

Candida albicans is a major fungal pathogen of humans. It exists as a commensal in the oral cavity, gut or genital tract of most individuals, constrained by the local microbiota, epithelial barriers and immune defences. Their perturbation can lead to fungal outgrowth and the development of mucosal infections such as oropharyngeal or vulvovaginal candidiasis, and patients with compromised immunity are susceptible to life-threatening systemic infections. The importance of the interplay between fungus, host and microbiota in driving the transition from C. albicans commensalism to pathogenicity is widely appreciated. However, the complexity of these interactions, and the significant impact of fungal, host and microbiota variability upon disease severity and outcome, are less well understood. Therefore, we summarise the features of the fungus that promote infection, and how genetic variation between clinical isolates influences pathogenicity. We discuss antifungal immunity, how this differs between mucosae, and how individual variation influences a person's susceptibility to infection. Also, we describe factors that influence the composition of gut, oral and vaginal microbiotas, and how these affect fungal colonisation and antifungal immunity. We argue that a detailed understanding of these variables, which underlie fungal-host-microbiota interactions, will present opportunities for directed antifungal therapies that benefit vulnerable patients.<br /> (© The Author(s) 2020. Published by Oxford University Press on behalf of FEMS.)

Details

Language :
English
ISSN :
1574-6976
Volume :
45
Issue :
3
Database :
MEDLINE
Journal :
FEMS microbiology reviews
Publication Type :
Academic Journal
Accession number :
33232448
Full Text :
https://doi.org/10.1093/femsre/fuaa060